louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02572154: Sperm DNA Fragmentation in Recurrent Pregnancy Loss
Official title: Male Factor in Early Recurrent Pregnancy Loss : Study of Sperm DNA Fragmentation in Patients With Unexplained Recurrent Pregnancy Loss.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: RECURRENT PREGNANCY LOSS
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2015-10-08
Enrollment: 64
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: In human, 2% of couples experimented Recurrent pregnancy loss (RPL). Currently, while etiological investigations were performed, 40 to 50 % of RPL were unexplained. In animals' studies, several studies have underlined the importance of sperm quality for a normal embryo development. In human, epidemiological studies have demonstrated that several male risk factors have effects on development (male mediated development toxicology). However, few studies have explored sperm DNA fragmentation on embryo development but after in vitro fertilization. In natural pregnancy only rare studies have been performed but with different populations definitions and different methods of sperm exploration. In this context sperm DNA fragmentation exploration appears justified. The present study purpose to conduct a case - control study in order to research paternal role in RPL.


Eligibility criteria: Inclusion Criteria:

* Cases: Man from couples with RPL (more than 2 miscarriages) RPL classical etiological exploration negative (unexplained RPL) Healthy voluntaries
* Control: Man from couples who have a child after a natural pregnancy obtained in the year following child desire.

Healthy voluntaries

Exclusion Criteria:

* Cases: Etiological exploration of RPL positive Man with chromosomal anomaly
* Cases and controls:

Ongoing pathology Chemotherapy or radiotherapy history Hyperthermia (fever) in the last three months Pregnancy obtained by assisted reproduction (Inseminations, in vitro fertilization) Women \> 38 year old

Primary outcomes:
measure: sperm DNA fragmentation
timeFrame: baseline
Secondary outcomes:
measure: Sperm aneuploidy
timeFrame: baseline
measure: Sperm Volume
timeFrame: baseline
measure: Sperm pH
timeFrame: baseline
measure: sperm concentration
timeFrame: baseline
measure: sperm concentration of round cells
timeFrame: baseline
measure: percentage of motile and morphologically normal spermatozoa in sperm
timeFrame: baseline
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Chu Bordeaux
city: Marseille
country: France
facility: APHM
city: Toulouse
country: France
facility: Chu Toulouse
Study officials:
affiliation: CHU Toulouse
name: Louis Bujan, PUPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00826254: Nutritional Problems After Lung and Heart Transplantation
Official title: Nutritional Problems After Lung and Heart Transplantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bone Density
Overweight
Keywords: vitamin K
Bone Mineral Density
undercarboxylated osteocalcin
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Norwegian Foundation for Health and Rehabilitation
First posted: 2009-01-22
Enrollment: 94
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Part 1) Bone health after transplantation - possible influence of vitamin K

Part 2) Fat metabolism and endocrine parameters - possible predictors for developement of overweight after transplantation


Eligibility criteria: Inclusion Criteria:

* accepted for transplantation

Exclusion Criteria:

* not accepted for transplantation

Primary outcomes:
measure: plasma vitamin K
timeFrame: 1 year
Secondary outcomes:
measure: Bone mineral density
timeFrame: 1 year
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Rikshospitalet HF
Study officials:
affiliation: Oslo University Hospital
name: Liv Forli, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Oslo University Hospital
name: Liv Forli, Dr
role: STUDY_DIRECTOR
affiliation: Oslo University Hospital
name: Oystein Bjortuft, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04880954: Manual Therapy and Rehabilitation on Pain and Physical Functioning for Chronic Knee Pain
Official title: Soft Tissue Mobilization and Rehabilitation on Pain and Physical Functioning for Non-Specific Chronic Knee Pain: A Randomized Clinical Trail
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Non-Specific Chronic Knee Pain
Lead sponsor: Neuro Performance Integration
Sponsor class: OTHER
First posted: 2021-05-11
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to one of three groups 1) Manual Therapy, 2) Rehabilitation, or 3) Combination of both
Primary purpose: TREATMENT

Brief summary: This is a research study examining if hands-on therapy and prescribed exercise is an effective way to manage and reduce knee pain. It will also look at physical benefits of this treatment including balance, strength, and flexibility.

Participation will include 2 assessment days and a 12-week treatment cycle. Assessments will be conducted during week 1 and after treatment. The treatment will vary based on the assigned group. This may include 12 in-person manual therapy sessions occurring once per week and or 12-weeks of at-home therapy occurring 5 times per week.

The greatest risk of participation includes possible muscle/joint soreness, injury during at-home exercises, and loss of confidentiality.


Eligibility criteria: Inclusion Criteria:

* Adults experiencing non-specific knee pain for 3 or more months. Pain must be 3/10 (VAS) or higher.

Exclusion Criteria:

* Pain due to knee surgery, fracture, tumor, trauma, or those on medication for mood disorder (assessed on case by case basis).

Primary outcomes:
measure: Change in Perceived Pain
timeFrame: This will be measured pre- and post- intervention (week 1 and week 13).
Secondary outcomes:
measure: Range of Motion
timeFrame: This will be measured pre- and post- intervention (week 1 and week 13)
measure: Modified Clinical Test of Sensory Integration and Balance
timeFrame: This will be measured pre- and post- intervention (week 1 and week 13).
measure: Isometric Strength
timeFrame: This will be measured pre- and post- intervention (week 1 and week 13).
measure: Limits of Stability
timeFrame: This will be measured pre- and post- intervention (week 1 and week 13).
Other outcomes:
Locations:
city: Park City
country: United States
facility: Neuro Performance Integration
state: Utah
Study officials:
affiliation: Neuro Performance Integration
name: Beverly Albert, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05958654: DETECT-RPC Universal EM Screening
Official title: Detection of Elder Mistreatment Through Emergency Care Technicians - Revised for Primary Care (DETECT-RPC) Universal EM Screening
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Elder Abuse
Elder Mistreatment
Keywords: Elder Mistreatment
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2023-07-24
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to evaluate whether the use of the Detection of Elder Mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool increases the average reporting of elder mistreatment (EM) by homebased primary care (HBPC) clinicians.


Eligibility criteria: Inclusion Criteria (Clinicians):

* Clinician who actively provides home-based primary care (HBPC) to patients enrolled in one of our partner home-based primary care programs at least part time.

Exclusion Criteria (Clinicians):

* HBPC Clinicians must be a physician, nurse practitioner, or physician assistant who actively provides home-based primary care to patients enrolled at a partner site HBPC at least part time

Inclusion Criteria (patients):

* in home-based primary care
* 60 years or older
* seen by a clinician participating in the study

Exclusion Criteria (patients)

* Must be aged 60 and older, enrolled in a site-specific partner HBPC and treated in their primary residence

Primary outcomes:
measure: number of reports of EM
timeFrame: from randomization to termination of data collection (3 years)
measure: Mortality
timeFrame: from randomization to termination of data collection (3 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Baltimore
country: United States
facility: John Hopkins University Medicine International
state: Maryland
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
city: Houston
country: United States
facility: The University of Texas health Science Center at Houston( LBJ House Calls Program)
state: Texas
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston( UT Physicians House Calls Program)
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Michael B Cannell, PhD,MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06308354: Colorectal Cancer Dataset in Xijing Hospital From 2011
Official title: Colorectal Cancer Dataset in Xijing Hospital From 2011
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prognostic Cancer Model
Chemotherapy
Nutrition Related Cancer
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2024-03-13
Enrollment: 40000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.

Brief summary: To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.


Eligibility criteria: Inclusion Criteria:

* 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
* 2. Visit our center with complete medical records and pathological information;
* 3. Colorectal cancer patients diagnosed between 2013 and 2023.

Exclusion Criteria:

* 1. The patient has other colorectal malignancies other than adenocarcinoma;
* 2. Malignant tumors adjacent to organs invading the colon and rectum;
* 3. Malignant tumors from distant organs metastasize to the colon and rectum;
* 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.

Primary outcomes:
measure: overall survival
timeFrame: from date of diagnosis until the date of death from any cause, assessed up to 120 months
measure: DFS
timeFrame: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Fourth Military Medical University
state: Shaanxi
Study officials:
References:
Clinical trial NCT01318954: The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis
Official title: The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Allergic Asthma
Allergic Rhinitis
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Sponsor class: OTHER
First posted: 2011-03-21
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with allergic asthma and allergic rhinitis undergoing allergen immunotherapy

Brief summary: This study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy ("allergy shots"). The investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.


Eligibility criteria: Inclusion Criteria:

* Subjects over 18 years old with allergic asthma and/or allergic rhinitis who are beginning allergen desensitization

Exclusion Criteria:

* Smokers
* Subjects of dimished capacity

Primary outcomes:
measure: Effect of allergen immunotherapy on exhaled nitric oxide
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Bryn Mawr
country: United States
facility: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
state: Pennsylvania
Study officials:
affiliation: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
name: Michele Columbo, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02678754: Caris Molecular Intelligence Registry
Official title: A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation With Cancer Clinical Outcomes
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Solid Tumors
Lead sponsor: Caris Science, Inc.
Sponsor class: INDUSTRY
First posted: 2016-02-10
Enrollment: 4981
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: All patients seen within a physician practice participating in the Registry are potential candidates if they meet the eligibility criteria requirements

Brief summary: This data collection Registry is a multi-center, observational outcomes Database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, quality of life and outcomes of subjects utilizing Caris Molecular Intelligence™ Services for treatment of solid tumor cancer.


Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years, and
* Solid Tumor analyzed by Caris Molecular Intelligence™ Service Profile(s) and/or Caris Next-Generation Sequencing

Exclusion Criteria:

* Individual test orders; defined as single biomarker assessment
* Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoner-patients shall not be approached for participation in the Registry.

Primary outcomes:
measure: Documentation of the frequency of specific clinical events in relation to risk factors, diagnosis and treatments provided.
timeFrame: 5 years per patient
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02235454: SDOCT-GMPE Software
Official title: A Prospective Evaluation of the Novel Glaucoma Premium Edition Software for Spectral Domain Optical Coherence Tomography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: glaucoma
OCT
spectral domain optical coherence tomography
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-09-10
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators prospectively evaluate the new glaucoma premium edition (GMPE) software for spectral domain optical coherence tomography (SDOCT) and if this software is superior to the conventional one that is currently used for SDOCT.

Detailed description: The new GMPE software can now identify the ocular structures without input from the operator thus reducing operator induced errors. It also measures the thickness of the entire optic nerve head so as to allow for another anatomic area of the eye to be measured for assessment of glaucoma. In addition, it permits collection of retinal nerve fiber layer thickness data in three concentric circles instead of just one in order to account for different sizes of optic nerves.

Subjects who are receiving routine SDOCT (CPT 92133) will be recruited from the Duke Eye Center and its associated satellite clinics. Following informed consent, subjects undergo additional imaging using the SDOCT-GMPE software at the Duke Eye Center and its associated satellite clinics. The imaging results may be used in clinical care for the subjects.

Eligibility criteria: Inclusion Criteria:

* capable and willing to provide consent
* history of clinically-diagnosed glaucoma
* at least 18 years of age

Exclusion Criteria:

* unable or unwilling to give consent
* under 18 years of age

Primary outcomes:
measure: Retinal Nerve Fiber Layer (RNFL) Thickness Correlation Width Global Bruch's Membrane Opening-minimum Rim Width (BMO-MRW)
timeFrame: imaging approximately 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Eye Center
state: North Carolina
Study officials:
affiliation: Duke Health
name: Sanjay Asrani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03280654: Visceral Adiposity Index and Overactive Bladder
Official title: Visceral Adiposity Index and Overactive Bladder: A Novel Predictive Risk Factor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Visceral Adiposity Index
Keywords: Obesity
Overactive Bladder
Urinary incontinence
Visceral Adiposity Index
Waist Circumference
Lead sponsor: Recep Tayyip Erdogan University Training and Research Hospital
Sponsor class: OTHER
First posted: 2017-09-12
Enrollment: 9
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: female patients over 18 years aged with overactive bladder symptoms

Brief summary: In present study, we aimed to investigate the association between visceral adiposity index and overactive bladder symptoms in female patients aged over 18 years.Between January-2015 and July-2017, 151 female patient with overactive bladder symptoms were evaluated in Recep Tayyip Erdogan University Training and Research Hospital Urology Department. Antropometric and laboratory features including serum lipid levels, AST, ALT, fasting glucose levels, and also urodynamic findings were recorded. Visceral adiposity index was calculated according to gender-specific formula. Participants were divided into two groups according to 7,55 cut-off level for visceral adiposity index levels. Statistical significance were discussed between two groups.

Detailed description: Antropometric and laboratory features including serum lipid levels, AST, ALT, fasting glucose levels were recorded. Urodynamic study was performed all of patients to evaluate bladder functions. Over active bladder questionnaire-8 Turkish validated short form was filled out and recorded for each patients. Detailed medical histories of all patients were obtained before the study. Height, weight, and waist circumference (WC) were measured with the subjects in their underwear. Body mass ındex (BMI) was computed by the formula as the ratio of weight to the square of height (kg/m2). WC was measured on the line between the iliac crest and the lower costal margin parallel to the ground after subjects exhaled. Inclusion criteria of study was female patients who have over active bladder symptomes with or without urinary incontinence. Exclusion criterias of study were male gender, pregnancy, alcohol intake, bladder cancer history, previous incontinence surgery history, presence of neurological disease, urinary infection or bladder stone and pelvic radiotherapy history.

Eligibility criteria: Inclusion Criteria:

* Female patients over 18 years aged with overactive bladder symptoms

Exclusion Criteria:

* Male gender, pregnancy, alcohol intake, bladder cancer history, previous incontinence surgery history, presence of neurological disease, urinary infection or bladder stone and pelvic radiotherapy history

Primary outcomes:
measure: Visceral adiposity index
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01589354: Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery
Official title: Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Analgesia
Lead sponsor: NHS Grampian
Sponsor class: OTHER_GOV
First posted: 2012-05-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study evaluates two anaesthetic techniques namely interscalene brachial plexus block and intra-articular local anaesthetic injection. Both techniques are currently used for providing postoperative pain relief following arthroscopic shoulder stabilisation operation. It will be a randomised controlled trial involving 30 patients in two groups.


Eligibility criteria: Inclusion Criteria:

• All adult patients above the age of 18 years undergoing arthroscopic shoulder stabilisation operation

Exclusion Criteria:

* Patients not meeting inclusion criteria
* Patients unable to give informed consent
* Patient refusal to participate in the study
* Contraindications to Interscalene block
* Allergy to local anaesthetics
* Peripheral neuropathy from any cause
* Patients on opiates for chronic pain
* Pregnant women

Primary outcomes:
measure: Mean pain score over the first 24 hours following arthroscopic shoulder stabilisation operation
timeFrame: 24 months
Secondary outcomes:
measure: Post-operative analgesic requirements in the first 24 hours after surgery
timeFrame: 24 months
measure: Patient assessment of quality of analgesia and identifying any complications as a result of the two anaesthetic procedures
timeFrame: 24 months
Other outcomes:
Locations:
Study officials:
affiliation: NHS Grampian
name: Amr M Mahdy, MD
role: PRINCIPAL_INVESTIGATOR
References: